Caris Life Sciences Rated Neutral by Piper Sandler Piper Sandler initiated coverage of Caris Life Sciences with a Neutral rating on Apr 10, 2026 (Investing.com); institutional investors should seek the full note and monitor test volumes.

Caris Life Sciences Rated Neutral by Piper Sandler: Piper Sandler initiated coverage of Caris Life Sciences with a Neutral rating on Apr 10, 2026 (Investing.com); institutional investors should seek… 👈 Read full analysis #CarisLifeSciences #PiperSandler #Investment #HealthcareInvestment #Diagnostics

As year-end nears, pharma groups plump up their pipelines Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

#BristolMyersSquibb #Sanofi #Pfizer #Roche #YarrowBioscience #RandDpipelines #HarbourBioMed #Genentech #AI #CarisLifeSciences #CarisDiscovery #ADEL #phase1testing #DrenBio #drugdiscovery #immunology #oncology #rheumatology #Gravesdisease #GeneSciencePharma #GenSci
zurl.co/Kyjjn

How Real-World Data is Transforming Tissue-Agnostic Cancer Care - Caris Life Sciences - OncoDaily How Real-World Data is Transforming Tissue-Agnostic Cancer Care - Caris Life Sciences / Anthony Helmstetter, Brady Gilg, cancer, Caris Life Sciences, David

Caris Life Sciences - How Real-World Data is Transforming Tissue-Agnostic Cancer Care

@viveksubbiah.bsky.social

oncodaily.com/opinion/cari...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CarisLifeSciences

Click Subscribe #CarisLifeSciences #NasdaqDebut #StockMarketNews #Investing #Finance

Click Subscribe #CarisLifeSciences #IPO #StockMarket #Investing #FinancialNews

Caris Life Sciences IPO indicated to open at $30 after pricing at $21 Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #CarisLifeSciences #IPO #StockMarket #Investing #FinancialNews

Caris swells its planned IPO, seeking $5.7bn valuation AI-powered techbio firm Caris Life Sciences has raised the target price for its IPO, pointing to strong demand among investors.

#CarisLifeSciences, which specialises in the use of #AI to guide disease diagnosis, treatment selection, and patient monitoring, has raised the target price for its planned initial public offering (#IPO), seeking to raise up to $471 million.

pharmaphorum.com/news/caris-s...

Caris Life Sciences Raises Price Range of 23.53M Share IPO at $19-$20/sh Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #CarisLifeSciences #IPO #StockMarket #Investment #FinancialNews

Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO GH MRNAABBVXNCR hereremove ads C Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #CarisLifeSciences #IPO #Investing #StockMarket #CancerDiagnosis

Caris Life Sciences Launches IPO Caris Life Sciences (CAI) today announced that it has launched the roadshow for its proposed initial public offering of its common stock. Caris has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") to offer 23,529,412 shares of its common stock to the public. In addition, Caris intends to grant the underwriters a 30-day option to purchase up to an additional 3,529,411 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is expected to be between $16.00 and $18.00 per share. Caris has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol "CAI." BofA Securities, J.P. Morgan and Goldman Sachs & Co (NYSE:GS). LLC will act as lead book-running managers for the proposed offering. Citigroup (NYSE:C) will also act as a book-running manager for the proposed offering. TD Cowen, Evercore ISI and Guggenheim Securities will act as additional book-running managers for the proposed offering. BTIG and Wolfe | Nomura Alliance will act as co-managers for the proposed offering. The proposed offering will be made available only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: dg.prospectus_requests@bofa.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions (NYSE:BR), 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@jpmchase.com; or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282 or by email: prospectus-ny@ny.email.gs.com. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. C: A Bull or Bear Market Play? Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if C is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #CarisLifeSciences #IPO #Investing #StockMarket #FinancialNews

Funding Raises: #Chainguard $356M Series D; #Supabase $200M Series D; #Electra $186M Series B; #CarisLifeSciences $168M; #Ocient $132M Series B; #Flow $100M Series B; #Biolinq $100M Series C; #EndorLabs $93M Series B; #Noxtua €80.7M Series B; #Yulu $80M Series C